Externally Funded Doctoral Student (m­­/­­f­­/­­d) - Epigenetic Regulation of Pancreatic Cancer Cell Plasticity (Johnsen group)

The research group of Prof. Steven Johnsen is part of the Robert Bosch Center for Tumor Diseases (RBCT). The RBCT is a newly founded non-profit translational cancer research institute at the Bosch Health Campus in Stuttgart, in direct proximity to the Robert Bosch Hospital (RBK). As a part of the National Center for Tumor Diseases (NCT) Southwest and the Comprehensive Cancer Center Tübingen-Stuttgart, the RBCT is dedicated to innovative cancer research and the development of new treatment strategies. The Johnsen group has a particular and long-standing expertise in the elucidation of complex gene regulatory networks that control pancreatic cancer pathogenesis. In particular, we utilize state-of-the-art techniques such as various genome-/transcriptome-wide sequencing approaches, high-throughput CRISPR/Cas9-mediated screening, multiplex immunofluorescence staining of tissues, single cell RNA-sequencing, as well as genetic engineering and other work on tumor cell lines, primary patient samples and translational tumor models. Our main research goal is to identify gene regulatory mechanisms that can be exploited as novel therapeutic targets to improve treatment response and pancreatic cancer patient survival.